Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry

Abstract Background Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation. The introduction of biologics has improved the treatment options for SJIA. Canakinumab selectively inhibits...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Colleen Correll, Alis Burciu, Amita Bansal, Anne Dennos, Deepak Narayanswamy, Elodie Aubrun, Laura E. Schanberg, Li Yuhan, Rahel Schneider, Stephen Balevic, Yukiko Kimura, Timothy Beukelman, for the CARRA Registry investigators
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2025-10-01
סדרה:	Pediatric Rheumatology Online Journal
נושאים:	Systemic juvenile idiopathic arthritis Canakinumab CARRA registry Safety
גישה מקוונת:	https://doi.org/10.1186/s12969-025-01144-w
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!